p.82 抽出テキスト
161. Martín Gutiérrez E, Castaño M, Gualis J, Martinez-Comendador JM, Maiorano P, Castillo L, et al. Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients. Eur J Cardiothorac Surg 2020;57:252–62. https://doi. org/10.1093/ejcts/ezz289 162. Connolly SJ, Healey JS, Belley-Cote EP, Balasubramanian K, Paparella D, Brady K, et al. Oral anticoagulation use and left atrial appendage occlusion in LAAOS III. Circulation 2023;148:1298–304. https://doi.org/10.1161/CIRCULATIONAHA.122.060315 163. Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J, et al. Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation. Circulation 2024;149:734–43. https://doi. org/10.1161/circulationaha.123.067312 164. Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study. Ann Intern Med 2021;174:910–9. https://doi. org/10.7326/m20-6194 165. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022;387:978–88. https://doi.org/10.1056/NEJMoa2209051 166. Rankin JS, Grau-Sepulveda MV, Ad N, Damiano RJ Jr, Gillinov AM, Brennan JM, et al. Associations between surgical ablation and operative mortality after mitral valve procedures. Ann Thorac Surg 2018;105:1790–6. https://doi.org/10.1016/j.athoracsur.2017. 12.035 167. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al. Surgical ablation of atrial fibrillation in the United States: trends and propensity matched outcomes. Ann Thorac Surg 2017;104:493–500. https://doi.org/10.1016/j. athoracsur.2017.05.016 168. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015; 372:1399–409. https://doi.org/10.1056/NEJMoa1500528 169. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, et al. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database Syst Rev 2016;2016:CD011814. https://doi.org/10.1002/ 14651858.CD011814.pub2 170. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, et al. A prospective randomized trial of the cut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve disease. J Thorac Cardiovasc Surg 2018;155:608–17. https://doi.org/10.1016/j.jtcvs.2017. 07.084 171. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, et al. A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay. J Thorac Cardiovasc Surg 2014;148:955–61; discussion 962–952. https://doi.org/10.1016/j.jtcvs.2014.05.064 172. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, et al. Surgical ablation for atrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations (Phila) 2010;5:84–96. https://doi.org/10.1097/IMI.0b013e3181d9199b 173. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, et al. Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace 2018;20:1442–50. https://doi.org/10.1093/europace/eux336 174. Yoo JS, Kim JB, Ro SK, Jung Y, Jung SH, Choo SJ, et al. Impact of concomitant surgical atrial fibrillation ablation in patients undergoing aortic valve replacement. Circ J 2014; 78:1364–71. https://doi.org/10.1253/circj.cj-13-1533 175. Malaisrie SC, Lee R, Kruse J, Lapin B, Wang EC, Bonow RO, et al. Atrial fibrillation ablation in patients undergoing aortic valve replacement. J Heart Valve Dis 2012;21: 350–7. 176. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart 2016;102:269–76. https://doi.org/10.1136/heartjnl-2015-308765 177. Lee C, Hahn RT. Valvular heart disease associated with radiation therapy: a contemporary review. Struct Heart 2023;7:100104. https://doi.org/10.1016/j.shj.2022.100104 178. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013; 26:1013–32. https://doi.org/10.1016/j.echo.2013.07.005 179. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation 2013;127:1476–85. https://doi.org/10.1161/CIRCULATIONAHA. 113.001435 180. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, et al. Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J Am Heart Assoc 2017;6:e005396. https://doi.org/10.1161/JAHA.116.005396 181. Donnellan E, Alashi A, Johnston DR, Gillinov AM, Pettersson GB, Svensson LG, et al. Outcomes of patients with mediastinal radiation-associated mitral valve disease undergoing cardiac surgery. Circulation 2019;140:1288–90. https://doi.org/10.1161/ CIRCULATIONAHA.119.040546 182. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 183. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter compared with surgical aortic valve replacement in patients with previous chestdirected radiation therapy. JACC CardioOncol 2021;3:397–407. https://doi.org/10. 1016/j.jaccao.2021.07.005 184. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis. Cardiooncology 2020;6:8. https://doi.org/10. 1186/s40959-020-00062-y 185. Ullah W, Thalambedu N, Zahid S, Muhammadzai Hamza Zahid U, Sandhyavenu H, Kumar A, et al. Trends and outcomes of TAVI and SAVR in cancer and noncancer patients. JACC Adv 2023;2:100167. https://doi.org/10.1016/j.jacadv.2022.100167 186. Lind A, Totzeck M, Mahabadi AA, Janosi RA, El Gabry M, Ruhparwar A, et al. Impact of cancer in patients undergoing transcatheter aortic valve replacement: a single-center study. JACC CardioOncol 2020;2:735–43. https://doi.org/10.1016/j.jaccao.2020.11.008 187. Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990–2017. Circulation 2020;141:1670–80. https://doi.org/10.1161/ CIRCULATIONAHA.119.043391 188. Rwebembera J, Marangou J, Mwita JC, Mocumbi AO, Mota C, Okello E, et al. 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease. Nat Rev Cardiol 2023;21:250–63. https://doi.org/10.1038/s41569-023- 00940-9 189. Karki P, Uranw S, Bastola S, Mahato R, Shrestha NR, Sherpa K, et al. Effectiveness of systematic echocardiographic screening for rheumatic heart disease in Nepalese schoolchildren: a cluster randomized clinical trial. JAMA Cardiol 2021;6:420–26. https://doi.org/10.1001/jamacardio.2020.7050 190. Beaton A, Okello E, Rwebembera J, Grobler A, Engelman D, Alepere J, et al. Secondary antibiotic prophylaxis for latent rheumatic heart disease. N Engl J Med 2022;386: 230–40. https://doi.org/10.1056/NEJMoa2102074 191. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association. Circulation 2020;142:e337–57. https://doi.org/10.1161/cir.0000000000000921 192. World Health Organization. WHO Guideline on the Prevention and Diagnosis of Rheumatic Fever and Rheumatic Heart Disease. https://www.who.int/publications/i/ item/9789240100077 (28 March 2025, date last accessed). 193. Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, et al. Acute heart failure and valvular heart disease: a scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. Eur J Heart Fail 2023;25:1025–48. https://doi.org/10.1002/ejhf.2918 194. Lüsebrink E, Lanz H, Kellnar A, Karam N, Kapadia S, Makkar R, et al. (December 11, 2024) Management of acute decompensated valvular heart disease. Eur J Heart Fail, https://doi.org/10.1002/ejhf.3549 195. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, et al. Outcomes following urgent/emergent transcatheter aortic valve replacement: insights from the STS/ ACC TVT registry. JACC Cardiovasc Interv 2018;11:1175–85. https://doi.org/10.1016/ j.jcin.2018.03.002 196. Elbadawi A, Elgendy IY, Mentias A, Saad M, Mohamed AH, Choudhry MW, et al. Outcomes of urgent versus nonurgent transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2020;96:189–95. https://doi.org/10.1002/ccd.28563 197. Masha L, Vemulapalli S, Manandhar P, Balan P, Shah P, Kosinski AS, et al. Demographics, procedural characteristics, and clinical outcomes when cardiogenic shock precedes TAVR in the United States. JACC Cardiovasc Interv 2020;13:1314–25. https://doi.org/ 10.1016/j.jcin.2020.02.033 198. Goel K, Shah P, Jones BM, Korngold E, Bhardwaj A, Kar B, et al. Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J 2023;44:3181–95. https://doi.org/10.1093/eurheartj/ehad387 199. Buchwald AB, Meyer T, Scholz K, Schorn B, Unterberg C. Efficacy of balloon valvuloplasty in patients with critical aortic stenosis and cardiogenic shock—the role of shock duration. Clin Cardiol 2001;24:214–8. https://doi.org/10.1002/clc.4960240308 200. Moreno PR, Jang IK, Newell JB, Block PC, Palacios IF. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol 1994;23:1071–5. https://doi.org/10.1016/0735-1097(94)90592-4 201. Llah ST, Sharif S, Ullah S, Sheikh SA, Shah MA, Shafi OM, et al. TAVR vs balloon aortic valvotomy for severe aortic stenosis and cardiogenic shock: an insight from the national inpatient sample database. Cardiovasc Revasc Med 2023;55:1–7. https://doi.org/10. 1016/j.carrev.2023.05.006 202. Tang GHL, Estevez-Loureiro R, Yu Y, Prillinger JB, Zaid S, Psotka MA. Survival following edge-to-edge transcatheter mitral valve repair in patients with cardiogenic shock: a nationwide analysis. J Am Heart Assoc 2021;10:e019882. https://doi.org/10.1161/jaha.120. 019882 Downloaded from academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 07 October 2026